输注后1个月，CD8+ CAR T细胞通常占主导地位。其中一名患者的CD4和CD8表达在多个时间点被检测，持续时间最长达220天，但CD8表达始终占主导地位。

撰稿 | 郑诗蔚   责编 | 周叶斌近年来，靶向CD19的CAR T细胞疗法在治疗儿童和青少年复发或难治性急性淋巴细胞白血病（ALL）方面卓有成效，但约一半的患者在CAR ...

A research team from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences has revealed ...

上述结果表明，自体抗CD7 PEBL-CAR T细胞具有强大的抗白血病活性，是治疗T-ALL的潜在有效选择。这也意味着抗CD7 PEBL-CAR T细胞能够克服限制当前复发或难治性T-ALL治疗的耐药机制，为患者带来希望。

CD8-positive T cells are a critical subpopulation of MHC class I-restricted T cell and are mediators of adaptive immunity. They include cytotoxic T cells, which are important for killing cancerous ...